EGFR and non-small cell lung carcinoma: First-generation EGFR TKIs, such as gefitinib and erlotinib, selectively bind to ATP-binding sites of EGFR tyrosine kinase with non-covalent bond, thereby inhibiting EGFR phosphorylation and significantly delaying disease progression in targeted therapy for NSCLC in the clinic.